JP2005530735A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005530735A5 JP2005530735A5 JP2003585723A JP2003585723A JP2005530735A5 JP 2005530735 A5 JP2005530735 A5 JP 2005530735A5 JP 2003585723 A JP2003585723 A JP 2003585723A JP 2003585723 A JP2003585723 A JP 2003585723A JP 2005530735 A5 JP2005530735 A5 JP 2005530735A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutically acceptable
- acceptable salt
- medicament
- warm
- creating
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000003839 salts Chemical class 0.000 claims 16
- 239000011780 sodium chloride Substances 0.000 claims 16
- 239000003814 drug Substances 0.000 claims 6
- 238000004519 manufacturing process Methods 0.000 claims 6
- 230000001093 anti-cancer Effects 0.000 claims 2
- 230000000259 anti-tumor Effects 0.000 claims 2
- 230000000694 effects Effects 0.000 claims 2
- 230000002792 vascular Effects 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000000546 pharmaceutic aid Substances 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
Claims (8)
- ＺＤ６１２６またはその医薬的に許容できる塩およびＺＤ１８３９またはその医薬的に許容できる塩を、医薬的に許容できる賦形剤またはキャリヤーと共に含む医薬組成物。
- ＺＤ６１２６またはその医薬的に許容できる塩およびＺＤ１８３９またはその医薬的に許容できる塩を含むキット。
- ヒトなどの温血動物において血管破損効果の創出に用いるための医薬の製造における、ＺＤ６１２６またはその医薬的に許容できる塩およびＺＤ１８３９またはその医薬的に許容できる塩の使用。
- 電離性放射線で処置されているヒトなどの温血動物において血管破損効果の創出に用いるための医薬の製造における、ＺＤ６１２６またはその医薬的に許容できる塩およびＺＤ１８３９またはその医薬的に許容できる塩の使用。
- ヒトなどの温血動物において抗癌効果の創出に用いるための医薬の製造における、ＺＤ６１２６またはその医薬的に許容できる塩およびＺＤ１８３９またはその医薬的に許容できる塩の使用。
- 電離性放射線で処置されているヒトなどの温血動物において抗癌効果の創出に用いるための医薬の製造における、ＺＤ６１２６またはその医薬的に許容できる塩およびＺＤ１８３９またはその医薬的に許容できる塩の使用。
- ヒトなどの温血動物において抗腫瘍効果の創出に用いるための医薬の製造における、ＺＤ６１２６またはその医薬的に許容できる塩およびＺＤ１８３９またはその医薬的に許容できる塩の使用。
- 電離性放射線で処置されているヒトなどの温血動物において抗腫瘍効果の創出に用いるための医薬の製造における、ＺＤ６１２６またはその医薬的に許容できる塩およびＺＤ１８３９またはその医薬的に許容できる塩の使用。
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0208680A GB0208680D0 (en) | 2002-04-16 | 2002-04-16 | Combination therapy |
| GB0218388A GB0218388D0 (en) | 2002-08-08 | 2002-08-08 | Combination therapy |
| PCT/GB2003/001617 WO2003088971A1 (en) | 2002-04-16 | 2003-04-14 | Combination therapy for the treatment of cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2005530735A JP2005530735A (ja) | 2005-10-13 |
| JP2005530735A5 true JP2005530735A5 (ja) | 2006-05-11 |
Family
ID=29252451
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003585723A Pending JP2005530735A (ja) | 2002-04-16 | 2003-04-14 | 癌の処置のための併用療法 |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US20050215530A1 (ja) |
| EP (1) | EP1496909B1 (ja) |
| JP (1) | JP2005530735A (ja) |
| KR (1) | KR20040103964A (ja) |
| CN (1) | CN100352441C (ja) |
| AT (1) | ATE353650T1 (ja) |
| AU (1) | AU2003216558B2 (ja) |
| BR (1) | BR0309226A (ja) |
| CA (1) | CA2482591A1 (ja) |
| DE (1) | DE60311788T2 (ja) |
| ES (1) | ES2280735T3 (ja) |
| HK (1) | HK1071310A1 (ja) |
| IL (1) | IL164564A0 (ja) |
| MX (1) | MXPA04010166A (ja) |
| NO (1) | NO20044498L (ja) |
| NZ (1) | NZ535739A (ja) |
| WO (1) | WO2003088971A1 (ja) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0218526D0 (en) * | 2002-08-09 | 2002-09-18 | Astrazeneca Ab | Combination therapy |
| BRPI0411567A (pt) * | 2003-06-18 | 2006-08-01 | Angiogene Pharm Ltd | uso de zd6126 ou um seu sal farmaceuticamente aceitável e um dentre 5-fu, cpt-11, e 5-fu e cpt-11, composição farmacêutica, kit, e, métodos para a produção de um efeito de dano vascular em um animal de sangue quente e para o tratamento de um cáncer envolvendo um tumor sólido em um animal de sangue quente |
| WO2005037836A2 (en) * | 2003-10-15 | 2005-04-28 | Osi Pharmaceuticals, Inc. | Imidazo ‘1, 5 - a ! pyrazine tyrosine kinase inhibitors |
| DK1740591T3 (da) * | 2004-04-02 | 2009-10-26 | Osi Pharm Inc | Heterobicykliske proteinkinaseinhibitorer substitueret med en 6,6-biocyclisk ring |
| KR20070030240A (ko) * | 2004-06-03 | 2007-03-15 | 스미스클라인 비이참 (코르크) 리미티드 | 암 치료 방법 |
| AU2005249206A1 (en) | 2004-06-03 | 2005-12-15 | F. Hoffmann-La Roche Ag | Treatment with cisplatin and an EGFR-inhibitor |
| US20060084666A1 (en) * | 2004-10-18 | 2006-04-20 | Harari Paul M | Combined treatment with radiation and an epidermal growth factor receptor kinase inhibitor |
| FR2886151B1 (fr) * | 2005-05-31 | 2007-09-07 | Mayoly Spindler Soc Par Action | Utilisation de la colchicine pour la preparation d'un medicament destine a la prevention et/ou au traitement de l'endometriose |
| US8575164B2 (en) * | 2005-12-19 | 2013-11-05 | OSI Pharmaceuticals, LLC | Combination cancer therapy |
| WO2009091939A1 (en) * | 2008-01-18 | 2009-07-23 | Osi Pharmaceuticals, Inc. | Imidazopyrazinol derivatives for the treatment of cancers |
| JP2011520970A (ja) * | 2008-05-19 | 2011-07-21 | オーエスアイ・フアーマスーテイカルズ・インコーポレーテツド | 置換されたイミダゾピラジン類およびイミダゾトリアジン類 |
| US20120064072A1 (en) | 2009-03-18 | 2012-03-15 | Maryland Franklin | Combination Cancer Therapy Comprising Administration of an EGFR Inhibitor and an IGF-1R Inhibitor |
| MX2011011025A (es) | 2009-04-20 | 2011-11-02 | Osi Pharmaceuticals Llc | Preparacion de c-piracin-metilaminas. |
| WO2010129740A1 (en) * | 2009-05-07 | 2010-11-11 | Osi Pharmaceuticals, Inc. | Use of osi-906 for treating adrenocortical carcinoma |
| WO2012129145A1 (en) | 2011-03-18 | 2012-09-27 | OSI Pharmaceuticals, LLC | Nscle combination therapy |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU661533B2 (en) * | 1992-01-20 | 1995-07-27 | Astrazeneca Ab | Quinazoline derivatives |
| GB9508538D0 (en) * | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quinazoline derivatives |
| GB9714249D0 (en) * | 1997-07-08 | 1997-09-10 | Angiogene Pharm Ltd | Vascular damaging agents |
| EE200200565A (et) * | 2000-03-31 | 2004-06-15 | Angiogene Pharmaceuticals Ltd. | Vaskulaarse kahjustava toimega kombinatsioonravi |
| GB0008269D0 (en) * | 2000-04-05 | 2000-05-24 | Astrazeneca Ab | Combination chemotherapy |
-
2003
- 2003-04-14 AT AT03712464T patent/ATE353650T1/de not_active IP Right Cessation
- 2003-04-14 NZ NZ535739A patent/NZ535739A/en unknown
- 2003-04-14 KR KR10-2004-7016666A patent/KR20040103964A/ko not_active Application Discontinuation
- 2003-04-14 US US10/511,744 patent/US20050215530A1/en not_active Abandoned
- 2003-04-14 ES ES03712464T patent/ES2280735T3/es not_active Expired - Lifetime
- 2003-04-14 DE DE60311788T patent/DE60311788T2/de not_active Expired - Fee Related
- 2003-04-14 AU AU2003216558A patent/AU2003216558B2/en not_active Ceased
- 2003-04-14 WO PCT/GB2003/001617 patent/WO2003088971A1/en active IP Right Grant
- 2003-04-14 BR BR0309226-7A patent/BR0309226A/pt not_active IP Right Cessation
- 2003-04-14 EP EP03712464A patent/EP1496909B1/en not_active Expired - Lifetime
- 2003-04-14 CA CA002482591A patent/CA2482591A1/en not_active Abandoned
- 2003-04-14 CN CNB03813702XA patent/CN100352441C/zh not_active Expired - Fee Related
- 2003-04-14 MX MXPA04010166A patent/MXPA04010166A/es active IP Right Grant
- 2003-04-14 JP JP2003585723A patent/JP2005530735A/ja active Pending
-
2004
- 2004-10-13 IL IL16456404A patent/IL164564A0/xx unknown
- 2004-10-21 NO NO20044498A patent/NO20044498L/no not_active Application Discontinuation
-
2005
- 2005-05-23 HK HK05104297A patent/HK1071310A1/xx not_active IP Right Cessation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2006504723A5 (ja) | ||
| JP2005511597A5 (ja) | ||
| IL171683A (en) | Immunosuppressive Compounds, Medicinal Products Containing Them and Their Use in the Preparation of Medication for Treatment | |
| JP2005530735A5 (ja) | ||
| IL184051A (en) | Acetylated GLP-1 compounds, containing and using pharmaceutical preparations | |
| JP2008514577A5 (ja) | ||
| IL213597A0 (en) | Compounds, pharmaceutical compositions comprising them and their use in the manufacture of medicaments | |
| IL231576A (en) | Derivatives of adamantyl-acetamide, the pharmaceutical compositions containing them and their use in the preparation of medicines | |
| JP2006500346A5 (ja) | ||
| WO2006050155A3 (en) | Cancer therapeutic compositions | |
| IL165532A (en) | History of Aryl Carbonyl, Pharmaceutical Preparations Containing Them and Their Use in the Preparation of Medicines for the Treatment of Metabolic Disorders | |
| IL178822A (en) | Amide @@ - @Phenylamino-Quinzoline-6-YL, medicinal preparations containing them, and their use in the preparation of drugs for the treatment of proliferative disorders | |
| IL179714A (en) | Pharmaceutical preparation containing a history of 2-biphenyl-4-ram-3,2-dehydro-1h-quinazoline-4-on and its use in the preparation of cancer drugs and blood vessel formation | |
| IL189500A (en) | 4, 2-Diaminopyrimidines are preserved in position 5, containing pharmaceutical preparations and using them to prepare a drug for the treatment of 3x2p receptor mediated diseases and 2/3 x2p | |
| ZA200805163B (en) | Isoquinoline aminopyrazole derivatives, their manufacture and use as pharmaceutical agents for the treatment of cancer | |
| LT2526771T (lt) | Brutono tirozinkinazės inhibitoriai | |
| CL2003002287A1 (es) | COMPUESTOS DERIVADOS DE TIENO[3,2-b]-PIRIDINA-6-CARBONITRILOS Y TIENEO[2,3-b]-PIRIDINA-5-CARBONITRILOS, COMPOSICION FARMACEUTICA, PROCEDIMIENTO DE PREPARACION Y COMPUESTOS INTERMEDIARIOS, Y SU USO EN EL TRATAMIENTO DEL CANCER, APOPLEJIA, OSTEOPOROSIS | |
| WO2006053049A3 (en) | Herbal composition phy906 and its use in chemotherapy | |
| JP2012524089A5 (ja) | ||
| HK1105886A1 (en) | Pharmaceutical compositions comprising l-733060 for use in the treatment of cancer tumours l-733060 | |
| IL178939A (en) | Double and triple combinations suitable for synergistic treatment of breast cancer, including pharmaceuticals and their use in the manufacture of drugs and drugs for the treatment of breast cancer | |
| IL209879A0 (en) | Substituted pteridines ,pharmaceutical compositions containing them and their use in the manufacture of medicaments for treating inflammatory diseases | |
| IL179075A (en) | Use of random copolymer preparations in the preparation of drugs for the treatment of diseases, the reduction of undesirable immune reactions and the treatment of multiple sclerosis and pharmaceutical preparations containing random copolymer preparations | |
| IL172704A (en) | Pharmaceuticals containing salinosporamide compound and use of this compound for the preparation of a cancer drug | |
| ATE146361T1 (de) | Therapeutische mittel für die behandlungder resistenz gegen arzneimittel bei krebs |